Recce Ltd has released a press release.
Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
- Preliminary Final Report
- R327G Highly Effective in Burn Wounds Model
- Recce Signs Debt Facility with Avenue Capital Group
- Successful Placement of Entitlement Offer Shortfall
Later from Recce Pharmaceuticals
- Hong Kong Patent Granted for RECCE Anti-Infectives
- RCE Awarded Advanced Overseas Finding up to A$85m
- AUD $5.3m R&D Rebate Received
- Quarterly Activities/Appendix 4C Cash Flow Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals